Abstract
dc:description.abstractProblem: There is gap in time from when a Tepezza (teprotumumab) order is placed until the time a patient receives their first infusion. Context: Delays in the initiation of Tepezza infusions result in worsening symptoms and a decrease in quality of life for patients diagnosed with thyroid eye disease. Interventions: Interventions included scheduling regular meetings with involved departments, following each patient who has been prescribed Tepezza through the initiation of therapy, and improving staff and patient education. Measures: Outcome measures include decreasing days from order placement to first infusion from an average of 61 days to 30 days or less and increasing patient education and satisfaction. Process measures consist of establishing regular meetings with stakeholders, following patients from order to first infusion to collect data, creating a patient education pamphlet, and initiating a patient satisfaction survey. Balancing measures include maintaining regular meetings with stakeholders to assure that other involved departments do not sustain additional burden with new clinic workflows. Results: At the end of this project, 96% of patients receive their first dose of Tepezza within 30 days from the time the order was initiated. Conclusions: A timely benefits investigation, in addition to improved communication amongst stakeholders, led to the improvement in the previous delays in care.
Degree
thesis:*- Name thesis:degree_name
- Master of Science in Nursing (MSN)
- Level thesis:degree_level
- Project/Capstone - Global access
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Page, Rebecca D
- Contributors dc:contributor
-
- Dr. Susan Mortell
Subjects
dc:subject × 7Identifiers
dc:identifier.*- Repository record dc:identifier
- https://repository.usfca.edu/capstone/1398